Sep 28, 2026 · Science & Research Daily Digest
Science, space, biomedicine, and climate research highlights compiled for Sep 28, 2026, with summaries, links, and brief commentary.
I. Spaceflight and Deep Space
1. Starship Flight 14 reaches orbit and deploys 26 Starlink V3 satellites (Spaceflight)
Summary:
Space.com and the Associated Press, via CBC, reported on Sep 28 that SpaceX launched Starship's 14th full-scale test from Starbase, Texas, at 8:48 a.m. EDT. One of six engines on the Ship upper stage shut down early, and flight controllers continued; about 25 minutes after liftoff, Ship fired a single Raptor briefly and mission control confirmed that Starship was orbital. Ship then released 26 next-generation Starlink V3 satellites over about 30 minutes, the first of that generation placed in an operational orbit. The plan had been about six orbits and a splashdown off Chile 9 hours 50 minutes after launch. Controllers ended the flight early: the upper stage splashed down intact in the northern Pacific 3 hours 8 minutes after liftoff, then toppled and exploded. Super Heavy splashed down in the Gulf of Mexico as planned. Space.com cites SpaceX specifications for a stack about 124 meters tall. The two reports disagree on later Artemis dates, so this digest does not adopt a single schedule.
Links:
- Space.com — SpaceX launches Starship into orbit for 1st time
- CBC News — SpaceX sends giant Starship into orbit for the first time but ends the flight early
Commentary:
Orbit and an operational satellite deployment clear a threshold; the shortened flight leaves long-duration orbit and upper-stage recovery still open.
2. Jupiter moon probe Juice completes its Earth gravity assist over the Indian Ocean (Deep space)
Summary:
The European Space Agency confirmed on Sep 28 that Jupiter Icy Moons Explorer (Juice) made its closest approach at 13:45 CEST (11:45 UTC), 8,640 km above the Indian Ocean. Earth's gravity deflected the trajectory by 20 degrees from the pre-flyby path and increased speed by 3.5 km/s. In the four weeks before the flyby, operators used only one small nudge out of six reserved opportunities. Extra tracking began on Aug 17 and continues until Oct 10. Just before closest approach the spacecraft was in Earth's shadow and on battery power, so the team prioritized instrument calibration relevant to Jupiter. The last Earth flyby is set for January 2029, with Jupiter arrival in 2031, followed by 35 flybys of the three large moons and a later orbit of Ganymede.
Links:
Commentary:
The assist preserves propellant for Jupiter and the icy moons; the science return still waits on arrival in 2031.
II. Astronomy and Nuclear Matter
3. CHIME detects hydrogen's glow from when the universe was about five billion years old, using only its own data (Cosmology)
Summary:
The University of British Columbia announced on Sep 28 that the Canadian Hydrogen Intensity Mapping Experiment (CHIME) has shown it can detect the faint radio glow of hydrogen using only its own data. The results appear today in The Astrophysical Journal. The signal comes from when the universe was about five billion years old and is based on 94 nights of observations from 2019. The team extracted it from cosmic background, human radio signals, and instrument noise, then spent more than a year testing the result. Arizona State University's Shabbir Shaikh said roughly two percent of the hydrogen was in neutral atomic form at that time, broadly consistent with other measurements. The telescope near Penticton, British Columbia, is run by the University of British Columbia, McGill University, the University of Toronto, the National Research Council of Canada, and other partners. Earlier CHIME cosmology relied on cross-correlation with galaxy surveys. This measurement uses only a small fraction of nearly seven years of data; the collaboration is extending the analysis toward a cosmic age of about three billion years.
Links:
Commentary:
A standalone detection frees intensity mapping from galaxy surveys, but a dark-energy constraint still depends on the years of data not yet analyzed.
4. STAR sees an approximately 5-sigma dip in transverse-momentum fluctuations at low collision energy (Nuclear physics)
Summary:
Scientific American on Sep 28 covered a STAR Collaboration result that Brookhaven National Laboratory announced on Sep 22 and that Physical Review Letters published the same day (DOI: 10.1103/2xsn-rgx3). In fixed-target gold-gold collisions at the Relativistic Heavy Ion Collider, the collaboration measured two-particle transverse-momentum correlations at 3.0–7.7 GeV per nucleon pair. In central collisions the fluctuations fall and then rise, departing from a smooth trend by about 5 sigma, with a minimum around 5.2–7.7 GeV. A transport model without a critical point reaches only about 2 sigma, and mid-central collisions about 1.4 sigma, which is not enough to claim non-monotonicity. Rutik Manikandhan of the University of Houston and Chunjian Zhang of Fudan University helped lead the analysis. The collaboration states that no single observable proves a QCD critical point, and other explanations remain open. RHIC operated from 2000 to 2026.
Links:
- Scientific American — Surprising result seen in primordial matter inside atom smasher
- Physical Review Letters — Nonmonotonicity of transverse momentum correlations in Au+Au collisions at RHIC (DOI: 10.1103/2xsn-rgx3)
Commentary:
The dip points the same way as a rise in heat capacity near a critical point, and it does not yet locate that point on the phase diagram.
III. Biomedicine
5. Briefly blocking succinate dehydrogenase recruits both muscle and scar cells in mouse hearts after infarction (Cardiovascular)
Summary:
Ahmed Mahmoud's group at Sanford Burnham Prebys and U.S. collaborators published in Nature Cardiovascular Research on Sep 28 (DOI: 10.1038/s44161-026-00881-9). The metabolite malonate temporarily blocks succinate dehydrogenase and shifts adult mouse heart metabolism closer to the neonatal pattern. DNA regions tied to regeneration and the cell cycle become more accessible in cardiomyocytes, while scar-forming programs in fibroblasts are suppressed. Blocking the enzyme only in cardiomyocytes produces a transient rise in proliferation that is not enough to improve function after a heart attack. Blocking it only in cardiac fibroblasts suppresses their activation, reduces scarring, and improves function. Sustained genetic disruption is not the same as temporary malonate. The authors' long-term aim is the more than 800,000 heart attacks each year in the United States; the evidence is still from mice.
Links:
- Newswise — Modifying heart cell metabolism unlocks self-repair after heart attack
- Nature Cardiovascular Research (DOI: 10.1038/s44161-026-00881-9)
Commentary:
Better function tracks with fibroblasts making less scar, not with cardiomyocyte proliferation alone.
6. FDA approves tavapadon, the first selective D1/D5 agonist for adults with Parkinson's disease (Neurology)
Summary:
AbbVie announced on Sep 28 that the U.S. Food and Drug Administration approved JUVMO (tavapadon) tablets for adults with Parkinson's disease, the first approved selective D1/D5 receptor agonist. It is taken once daily with or without levodopa. Approval rests on the Phase 3 TEMPO program. In TEMPO-3 at week 26, tavapadon 5–15 mg plus oral levodopa increased daily "on" time without troublesome dyskinesia by 1.7 hours, versus 0.6 hours for placebo plus levodopa; "off" time fell by 1.9 hours versus 0.9 hours. In an open-label extension to 85 weeks, 93% (96/103) of participants on tavapadon plus levodopa did not raise their levodopa dose, and 94% (257/273) of those not on levodopa had not started it. AbbVie expects U.S. availability in October 2026 and cites an estimate of more than 11 million people worldwide with Parkinson's disease. Common adverse events include nausea, headache, and dizziness.
Links:
Commentary:
The approval adds a D1/D5 path beside existing D2/D3 agonists; the open-label extension is not a substitute for controlled long-term endpoints.
7. MIT's data-efficient search yields solid mRNA lipid nanoparticles that keep full activity after more than two months at 37°C (Vaccines)
Summary:
Nature Biotechnology published on Sep 28 a paper with corresponding authors Robert Langer and Ana Jaklenec at the Massachusetts Institute of Technology (DOI: 10.1038/s41587-026-03331-w). Their AGENT framework couples high-throughput experiments with Bayesian optimization and finishes formulation screening in six iterations within one month. For two clinically relevant lipid nanoparticles representing Moderna (SM-102) and Pfizer-BioNTech (ALC-0315) compositions, water-free solid formulations made by vacuum drying retained 100% bioactivity after more than two months at 37°C. In rodents and nonhuman primates, antigen-specific immune responses were non-inferior to intramuscular injection of freshly prepared soluble vaccine. The paper addresses the cold chain and formats such as microneedle patches; it does not report a human trial.
Links:
Commentary:
Holding activity at 37°C speaks to the cold-chain bottleneck; a room-temperature label still needs human data that have not started.
IV. Energy, Climate, and Earth
8. ENN says EXL-50U measured hydrogen-boron fusion reactions, without a reported net energy gain (Fusion)
Summary:
The South China Morning Post reported on Sep 28 that ENN Group, based in Langfang, Hebei, announced that day that its spherical tokamak EXL-50U had produced hydrogen-boron fusion reactions, which the company called the first time a commercial fusion company had done so on its own device. The company described the result as high-parameter hydrogen-boron plasma control. Mainstream magnetic-confinement programs such as ITER in France still use deuterium-tritium fuel. A same-day industry report of the experiment said high-energy neutral beams and radio-frequency waves raised the nonthermal fast-proton fraction at the first resonance of the hydrogen-boron reaction, with a reaction rate above 1.0×10^8 per second, and that an international review accepted repeatable measurements of the proton spectrum and alpha particles. Public accounts do not give an energy gain or electricity output. This is a different claim from the device's 1-megaampere hydrogen-boron plasma current in April 2025.
Links:
- South China Morning Post — Chinese commercial reactor achieves nuclear fusion with clean hydrogen-boron fuel
- CINIE — ENN's Xuanlong-50U device achieves a hydrogen-boron fusion reaction
Commentary:
Hydrogen-boron fuel is neutron-light and abundant; this announcement is a reaction measurement by the company, not a net energy gain.
9. Microbial extracellular polymers enter mineral-associated soil carbon at least as fast as dead cells (Carbon cycle)
Summary:
Nature Geoscience published on Sep 28 a paper by Peipei Qian, Yichao Wu, Peng Cai, Qiaoyun Huang, and colleagues (DOI: 10.1038/s41561-026-02103-0), with coauthors including Caroline L. Peacock and Yong-Guan Zhu. Using oxygen-18 water, the team quantified extracellular polymeric substances released by microbes and applied the method to a national survey of cropland soils in China. Production rates of those polymers are comparable to microbial cellular residues, and the polymers are statistically associated with mineral-associated organic carbon. In carbon-13 microcosms, carbon from the extracellular polymers entered the mineral-associated pool at rates comparable to or higher than carbon from cellular residues. The authors treat the extracellular route as a previously under-quantified input to that pool.
Links:
Commentary:
A soil-carbon ledger that counts only dead cells misses a secreted pool of similar size that can bind to minerals.
10. A pressurized wind tunnel shows that the best tip-speed ratio changes when a turbine yaws (Wind energy)
Summary:
MIT News on Sep 28 described an open-access PNAS Nexus paper published on Sep 7 (DOI: 10.1093/pnasnexus/pgag303). John Kurelek of Queen's University, Michael Howland of MIT, Marcus Hultmark of Princeton, and colleagues placed a 15-centimeter model turbine in a tunnel pressurized to as much as 220 atmospheres, scanning yaw angle and tip-speed ratio at Reynolds numbers relevant to commercial machines. The paper says control strategies designed for ideal alignment need to change, because the tip-speed ratio that maximizes power depends on yaw. A unified wind-turbine model predicts that combined effect. MIT News says optimizing alignment, blade pitch, and tip speed could be worth tens of thousands of dollars per turbine per year; that figure is an estimate, not measured field revenue.
Links:
- MIT News — Pressurized experiments could help wind farms generate more power
- PNAS Nexus — Full dynamic similarity experiments of wind turbine aerodynamics (DOI: 10.1093/pnasnexus/pgag303)
Commentary:
The pressurized tunnel isolates variables that field tests cannot, and any revenue estimate still depends on turbine, price, and wind.
V. Chemistry
11. Mammalian cells make cyclo-octasulfur and use it to limit lipid peroxidation and ferroptosis (Sulfur chemistry)
Summary:
Chemistry World reported on Sep 28 the Science paper "Mammals produce cyclo-octasulfur to suppress lipid peroxidation and ferroptosis" (DOI: 10.1126/science.aec5473; bibliographic records date the paper to Sep 24). A team led by Uladzimir Barayeu of the Max Planck Institute for Polymer Research and Takaaki Akaike of Tohoku University detected cyclo-octasulfur (S8), the most stable elemental-sulfur allotrope, in mouse and human cells. S8 reaches millimolar concentrations in mitochondrial membranes and lipid droplets, and lipid-droplet-associated nitric oxide synthase contributes to its biosynthesis. S8 limits lipid peroxidation and suppresses ferroptosis. Intra-articular injection of solubilized S8 reduced lipid peroxidation in a mouse model of osteoarthritis. The paper describes an endogenous sulfur pool, not an approved therapy.
Links:
- Chemistry World — Elemental sulfur found in mammalian cells for first time
- Science — Mammals produce cyclo-octasulfur to suppress lipid peroxidation and ferroptosis (DOI: 10.1126/science.aec5473)
Commentary:
Cells synthesize and store S8, turning antioxidant defense into an endogenous sulfur pathway; any treatment claim is still a mouse result.
Today's Summary
- Spaceflight: Starship Flight 14 reached orbit and deployed 26 Starlink V3 satellites, then ended at 3 hours 8 minutes instead of nearly 10 hours. Juice passed 8,640 km above the Indian Ocean and gained 3.5 km/s.
- Medicine: The FDA approved tavapadon, the first selective D1/D5 drug for Parkinson's disease. MIT's solid mRNA lipid nanoparticles kept full bioactivity after more than two months at 37°C. In mice, a temporary block of succinate dehydrogenase improved heart function only when fibroblasts as well as muscle cells were involved.
- Earth and energy: ENN announced hydrogen-boron fusion reactions on EXL-50U without a net-energy figure. A national survey of Chinese cropland finds microbial extracellular polymers to be a major source of mineral-associated carbon.
- Basic science: CHIME measured hydrogen's glow from a cosmic age of about five billion years with its own data. STAR reported an approximately 5-sigma dip in transverse-momentum fluctuations in 3.0–7.7 GeV gold collisions; a critical point is not established.
Daily Framing:
Today was an orbit-and-mechanism day: Starship reached orbit for the first time and Juice bent its path at Earth, while heart metabolism, elemental sulfur, and extracellular soil carbon each supplied a testable mechanism rather than a finished application.
This digest is compiled from real-time search results and is for reference only.